Галерея 2585019
Галерея 2585019
25.02 — 25.06.2022 Зона Машин персональная выставка Мэт Коллишоу
18.06 — 27.11.2021 Infinite персональная выставка Чак Клоуз
23.04 — 08.06.2021 Альберт Олен. Онлайн Выставка. персональная выставка
12.02 — 22.04.2021 Малкольм Морли. Онлайн Выставка персональная выставка
26.11.2020 — 26.01.2021 Хельмар Лерский Онлайн Выставка персональная выставка
08.09 — 25.11.2020 Line Matters. Онлайн Выставка. персональная выставка Евгений Чубаров
15.08 — 28.12.2019 Naturally Naked групповая выставка Джордж Кондо
Джон Керрин
Кэрролл Данэм
Тони Мателли
Бьярне Мелгаард
Ясумаса Моримура
Питер Соул
09.11.2018 — 09.02.2019 персональная выставка Вим Дельвуа
08.06 — 10.10.2018 персональная выставка Вик Мюнис
02.02 — 02.06.2018 Альбион персональная выставка Мэт Коллишоу
28.09 — 16.12.2017 Land Of Mirrors персональная выставка Кейичи Танаами
23.06 — 10.09.2017 персональная выставка Питер Хелли
31.03 — 01.06.2017 персональная выставка Дэмиен Хёрст
18.11.2016 — 11.03.2017 персональная выставка Рон Арад
22.04 — 27.09.2016 You Better Call Saul персональная выставка Питер Соул
27.11.2015 — 02.03.2016 Mutated Reality групповая выставка Фрэнсис Бэкон
Чак Клоуз
Джордж Кондо
Вим Дельвуа
Кэррол Данэм
Kaws
Майк Келли
Тони Мателли
Малкольм Морли
Питер Соул
03.04 — 10.11.2015 персональная выставка Евгений Чубаров
14.11.2014 — 23.03.2015 персональная выставка Ли Уфан
26.06 — 01.11.2014 персональная выставка Вим Дельвуа
21.03 — 15.06.2014 групповая выставка Олаф Брёнинг
Тони Мателли
Джон Миллер
13.09.2013 — 28.02.2014 Electric Spirit персональная выставка Ансельм Рейле
21.09 — 30.12.2010 персональная выставка Питер Хелли
28.04 — 08.08.2010 персональная выставка Стефан Балкенхол
01.03 — 21.04.2010 Persona Grata групповая выставка Джордж Кондо
Роберт Лукандер
Стефан Балкенхол
Мартин Малони
Вик Мюнис
Джоэл-Питер Уиткин
23.09 — 28.12.2009 The Idiot персональная выставка Тони Мателли
20.01 — 10.04.2009 Price of Oil групповая выставка Кристин Калабриз
Вик Мюнис
Тал Р
Евгений Чубаров
Мартин Малони
Роберт Лукандер
Лиза Райтер
18.09 — 30.12.2008 Survival персональная выставка Тони Мателли
15.05 — 14.08.2008 Artificial Realism персональная выставка Джордж Кондо
15.04 — 14.05.2008 Bad planet групповая выставка Джордж Кондо
Антон Хеннинг
Дэвид Лашапель
Тони Мателли
Райан Макгиннесс
Джонатан Мезе
Джон Миллер
Сара Моррис
Рокси Пейн
Андреас Сломинский
07.02 — 10.03.2008 персональная выставка Хельмар Лерский
01.11.2007 — 30.01.2008 Russian Project персональная выставка Вик Мюнис
25.09 — 30.10.2007 Up Close and Personal персональная выставка Мартин Малони
22.06 — 06.08.2007 персональная выставка Андре Бутцер
17.05 — 20.06.2007 персональная выставка Евгений Чубаров
02.03 — 20.04.2007 Hunky Dory групповая выставка Джонатан Мезе
Питер Доиг
Кристофер Вул
Крис Офили
Сесили Браун
Даниэль Рихтер
Тал Р
Дэш Сноу
Джордж Базелиц
Норберт Швонтковски
24.01 — 01.03.2007 Create Your Own Museum групповая выставка Айкон
Казимир Малевич
Александр Родченко
Евгений Чубаров
Реми Цаугг
Джейк и Динос Чэпман
Даниэль Рихтер
Стефан Балкенхол
Ласло Мохой-Наги
Дирк Скребер
Питер Хелли
Сара Моррис
Вик Мюнис
Джордж Кондо
Антон Хеннинг
18.10 — 30.11.2006 One Artist's Theater персональная выставка Ясумаса Моримура
17.05 — 05.08.2006 персональная выставка Питер Хелли
12.04 — 15.05.2006 The Art Of Chess групповая выставка Маурицио Каттелан
Дэмьен Хёрст
Пол Маккарти
Джейк и Динос Чапмэн
Яное Кусама
Мэтью Роней
Том Фридман
Тунга
Рэйчел Уайтрид
Барбара Крюгер
03.02 — 10.04.2006 House Of Prince персональная выставка Тал Р
28.10.2005 — 30.01.2006 персональная выставка Джоэл-Питер Уиткин
21.09 — 15.11.2005 персональная выставка Виджи
25.05 — 31.08.2005 Fresh Kills персональная выставка Алексис Рокман
10.02 — 15.05.2005 We can do it групповая выставка Кристин Калабрезе
Вик Мюнис
Торбин Гилер
Энтони Гормли
Питер Хелли
Стефан Балкенхол
Тони Мателли
Тони Оуслер
Home
About Us
Structure
News
Products
Stock
Cooperate
Order
Contact Us
中文
Sichuan Zhongbang New Material Co.,Ltd
Add:Taifu Lingang Industrial Zone, Luxian County, Luzhou City, Sichuan Province
PC:646000
Tel:+86-830-2585019
+86-13679670161 Yu Manager
Fax:+86-830-2589033
Email: yxp0808@zhongbangxcl.com
Sichuan Zhongbang New Material Co.,Ltd is specializing in the research, development, manufacturing and trade of fine chemicals, pesticide intermediates and Pharmaceutical intermediates; she has the main products line of 5000tons of 2,5-dimethyl-2,5-hexanediol, which is used as intermediate material in producing of pyrethrin, spice, synthetic muskiness, polyether rubber and cross-linking agent of polyethylene plastics,as well as in manufacturing of surfactant,she has a product line of 3000tons of Adamantane, 800tons of 3-Amino- ...
Прокси-сервер отказывается принимать соединения
Проверьте настройки прокси-сервера и убедитесь, что они верны.
Свяжитесь с вашим системным администратором и убедитесь, что прокси-сервер работает.
Firefox настроен на использование прокси-сервера, который отказывает в соединении.
Отправка сообщений о подобных ошибках поможет Mozilla обнаружить и заблокировать вредоносные сайты
Сообщить
Попробовать снова
Отправка сообщения
Сообщение отправлено
использует защитную технологию, которая является устаревшей и уязвимой для атаки. Злоумышленник может легко выявить информацию, которая, как вы думали, находится в безопасности.
iTeos Provides Business Updates and Clinical Development Plans for 2023
iTeos to Present at Cowen 43rd Annual Health Care Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...
iTeos s'apprête à effectuer une présentation lors de la SVB Securities Global Biopharma Conference
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 07 févr. 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la...
Newswire Distribution Network & Management Home Newsroom RSS Feeds Legal
© 2023 GlobeNewswire, Inc. All Rights Reserved.
We use cookies to improve your GlobeNewswire experience. By continuing, you agree to our use of cookies. For more information, please see our Privacy Policy .
January 09, 2023 07:00 ET
| Source:
iTeos Therapeutics Inc.
iTeos Therapeutics Inc.
Watertown, Massachusetts, UNITED STATES
- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant
- Eleven clinical trials planned or ongoing against multiple tumor types, across three pipeline programs
- EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies mid-2023
- Cash balance of $752MM as of September 30, 2022, expected to provide runway into 2026 through multiple inflection points across our portfolio
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 09, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.
“2022 was a successful year of execution with multiple trial initiations across both clinical programs. In 2023, we will continue to progress our broad clinical plan against validated targets and benefit from informative readouts across the field. We expect to advance EOS-448, our anti-TIGIT, antibody, into Phase 3 in combination with GSK’s ant-PD-1, Jemperli (dostarlimab) and also continue to advance studies targeting the adenosine pathway through our inupadenant program. Additionally, EOS-984, a first-in-class therapy designed to inhibit a novel target in the adenosine pathway, is expected to enter the clinic in mid-2023 and we are very encouraged by the preclinical data we have in hand,” said Michel Detheux, Ph.D., president, and chief executive officer of iTeos. “Leveraging our scientific expertise, drug development capabilities, financial resources, and our strong partnership with GSK, we are in an enviable position as we kick off 2023. Throughout the year we will continue to advance these novel combinations to unlock the next wave of immunotherapies, generating additional data and value as we work to bring forward new treatment options to people with cancer.”
EOS-448/GSK4428859A: IgG1 anti-TIGIT monoclonal antibody designed to engage the Fc gamma receptor (FcγR) and enhance the anti-tumor response through multifaceted mechanisms.
Adenosine Pathway Inupadenant (EOS-850): Designed as an insurmountable and highly selective small molecule antagonist of the adenosine A 2A receptor, the only high-affinity adenosine receptor expressed on multiple immune cells found in the tumor microenvironment. Highlights include:
EOS-984: First-in-class small molecule program targeting a novel mechanism in the adenosine pathway
Cash Position: The company’s cash and cash equivalent position was $752.2 million as of September 30, 2022. The company continues to expect its cash balance to provide runway into 2026 to support differentiated clinical programs for EOS-448 and inupadenant as well as advance preclinical programs targeting immunosuppression pathways.
About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A 2A receptor antagonist tailored to overcome cancer immunosuppression, into proof-of-concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com . The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
Forward-Looking Statements This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of EOS-448 and inupadenant; the potential of EOS-984 to fully reverse adenosine immune suppression in combination with inupadenant and other standards of care; our clinical plans and upcoming milestones for 2023, including producing significant advances and generating value, our plan to continue to progress our broad clinical plan against validated targets and benefit from informative readouts across the field, our expectation to progress EOS-448 into Phase 3 in combination with dostarlimab, continuing to advance studies targeting the adenosine pathway, and our expectation that EOS-984 will enter the clinic in mid-2023; the ability of our novel combinations to unlock the next wave of immunotherapies; and iTeos having cash runway into 2026 to support differentiated clinical programs for EOS-448 and inupadenant and advance preclinical programs targeting immunosuppression pathways.
These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: market conditions; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in iTeos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company’s cash runway do not indicate when the Company may access the capital markets.
Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law.
For further information, please contact: Investor Contact: Ryan Baker iTeos Therapeutics, Inc. Ryan.Baker@iteostherapeutics.com Media Contact: media@iteostherapeutics.com
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
GlobeNewswire is a newswire distribution network. Articles and other content published by GlobeNewswire are the legal responsibility of the author and GlobeNewswire accepts no liability for the content of such material. GlobeNewswire publishes content for informational purposes and makes no representations regarding, recommendation or invitation to engage in, any form of financial or investment activity, and does not endorse the content of any material published.
Девушка в латексе у которой член заставила силой парня делать минет
Красивая девушка перед камерой мастурбирует себе промежность и наслаждается
Кенна показывает свое гладкое голое тело